1
|
Abdel-Mottaleb MMA, Boi L, Barra M, Colin J, Berni L, Béduneau A, Moulari B, Pellequer Y. Lipoproteins as Drug Carriers for Cyclosporine A: Optimization of the Entrapment. MATERIALS (BASEL, SWITZERLAND) 2023; 16:1156. [PMID: 36770166 PMCID: PMC9918909 DOI: 10.3390/ma16031156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/18/2022] [Revised: 01/12/2023] [Accepted: 01/17/2023] [Indexed: 06/18/2023]
Abstract
Lipoproteins are natural nanostructures responsible for the transport of cholesterol and other lipids in the blood. They are characterized by having a lipophilic core surrounded by an amphiphilic shell composed of phospholipids, cholesterol and one or more apolipoproteins. Being endogenous carriers makes them suitable for drug delivery purposes. Here, we investigate the effect of lipoproteins' intricate composition on the entrapment efficiency of a model drug "Cyclosporine A" into the different types of lipoproteins, namely, HDL, LDL and VLDL. It was observed that the protein content of the lipoproteins had the highest effect on the entrapment of the drug with a correlation coefficient of 0.80, 0.81 and 0.96 for HDL, LDL and VLDL respectively. This was even confirmed by the effect of plasma on the association rate of lipoproteins and the drug. The second effective factor is the cholesterol concentration, while triglycerides and phospholipids had a negligible effect.
Collapse
Affiliation(s)
| | - Lorenza Boi
- Department of Drug Science and Technology, University of Turin, 10125 Turin, Italy
- PEPITE EA4267, Labex LipSTIC (ANR-11-LABX-0021), Université Franche-Comté, F-25000 Besançon, France
| | - Marina Barra
- Department of Drug Science and Technology, University of Turin, 10125 Turin, Italy
- PEPITE EA4267, Labex LipSTIC (ANR-11-LABX-0021), Université Franche-Comté, F-25000 Besançon, France
| | - Julie Colin
- PEPITE EA4267, Labex LipSTIC (ANR-11-LABX-0021), Université Franche-Comté, F-25000 Besançon, France
| | - Luisa Berni
- Department of Drug Science and Technology, University of Turin, 10125 Turin, Italy
- PEPITE EA4267, Labex LipSTIC (ANR-11-LABX-0021), Université Franche-Comté, F-25000 Besançon, France
| | - Arnaud Béduneau
- PEPITE EA4267, Labex LipSTIC (ANR-11-LABX-0021), Université Franche-Comté, F-25000 Besançon, France
| | - Brice Moulari
- PEPITE EA4267, Labex LipSTIC (ANR-11-LABX-0021), Université Franche-Comté, F-25000 Besançon, France
| | - Yann Pellequer
- PEPITE EA4267, Labex LipSTIC (ANR-11-LABX-0021), Université Franche-Comté, F-25000 Besançon, France
| |
Collapse
|
2
|
Scarcello E, Abdel-Mottaleb MMA, Beduneau A, Moulari B, Pellequer Y. Amelioration of murine experimental colitis using biocompatible cyclosporine A lipid carriers. Drug Deliv Transl Res 2020; 11:1301-1308. [PMID: 32794147 DOI: 10.1007/s13346-020-00835-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Lipoproteins are biodegradable and biocompatible natural carriers that can be utilized for the transport of hydrophobic drugs, such as cyclosporin A (CycloA), a calcineurin inhibitor utilized for the inflammatory bowel disease, such as ulcerative colitis. A major limitation in the drug treatment of inflammatory bowel disease is the inability to deliver the drug selectively toward the inflamed tissues. Nanotechnology-based drug delivery systems have led to an amelioration of the therapeutic selectivity, but still the majority of the entrapped drug is eliminated without exercising a therapeutic effect. The present study aimed to prepare three lipoprotein formulations (HDL-, LDL-, and VLDL-based) loaded with cyclosporin A for the treatment of colitis in a murine model. After an intravenous injection of a drug dose of 2 mg/kg, clinical activity (colon weight/length ratio) and therapeutic effects (evaluated by the inflammatory markers MPO and TNF-α) were compared with those of the untreated colitis control group. All CycloA-containing lipoproteins reduced clinical activity, with a significant decrease in the case of LDL-CycloA formulation, which also led to the higher therapeutic effect.
Collapse
Affiliation(s)
- Eleonora Scarcello
- PEPITE EA4267, Université Bourgogne Franche-Comté, F-25000, Besançon, France.,Department of Drug Science and Technology, University of Turin, Turin, Italy
| | - Mona M A Abdel-Mottaleb
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
| | - Arnaud Beduneau
- PEPITE EA4267, Université Bourgogne Franche-Comté, F-25000, Besançon, France
| | - Brice Moulari
- PEPITE EA4267, Université Bourgogne Franche-Comté, F-25000, Besançon, France
| | - Yann Pellequer
- PEPITE EA4267, Université Bourgogne Franche-Comté, F-25000, Besançon, France
| |
Collapse
|
3
|
Modern approaches to the ocular delivery of cyclosporine A. Drug Discov Today 2016; 21:977-88. [DOI: 10.1016/j.drudis.2016.04.002] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2015] [Revised: 03/01/2016] [Accepted: 04/05/2016] [Indexed: 12/29/2022]
|
4
|
Dai Z, Yu X, Hong J, Liu X, Sun J, Sun X. Development of a novel CsA-PLGA drug delivery system based on a glaucoma drainage device for the prevention of postoperative fibrosis. MATERIALS SCIENCE & ENGINEERING. C, MATERIALS FOR BIOLOGICAL APPLICATIONS 2016; 66:206-214. [PMID: 27207056 DOI: 10.1016/j.msec.2016.04.077] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/30/2015] [Revised: 04/11/2016] [Accepted: 04/21/2016] [Indexed: 10/21/2022]
Abstract
The formation of a scar after glaucoma surgery often leads to unsuccessful control of intraocular pressure, and should be prevented by using a variety of methods. We designed and developed a novel drug delivery system (DDS) comprising cyclosporine A (CsA) and poly(lactic-co-glycolic acid) (PLGA) based on a glaucoma drainage device (GDD) that can continuously release CsA to prevent postoperative fibrosis following glaucoma surgery. The CsA@PLGA@GDD DDS was observed by field emission scanning electron microscopy and revealed an asymmetric pore structure. Thermogravimetric analysis was performed to measure the weight loss and evaluate the thermal stability of the CsA@PLGA@GDD DDS. The in vitro drug release profile of the DDS was studied using high performance liquid chromatography, which confirmed that the DDS released CsA at a stable rate and maintained adequate CsA concentrations for a relatively long time. The biocompatibility of the DDS and the inhibitory effects on the postoperative fibrosis were investigated in vitro using rabbit Tenon's fibroblasts. The in vivo safety and efficacy of the DDS were examined by implanting the DDS into Tenon's capsules in New Zealand rabbits. Bleb morphology, intraocular pressure, anterior chamber reactions, and anterior chamber angiography were studied at a series of set times. The DDS kept the filtration pathway unblocked for a longer time compared with the control GDD. The results indicate that the CsA@PLGA@GDD DDS represents a safe and effective strategy for preventing scar formation after glaucoma surgery.
Collapse
Affiliation(s)
- Zhaoxing Dai
- Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China; Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University, Shanghai 200031, China
| | - Xiaobo Yu
- Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China; Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University, Shanghai 200031, China
| | - Jiaxu Hong
- Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China; Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University, Shanghai 200031, China
| | - Xi Liu
- Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China; Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University, Shanghai 200031, China
| | - Jianguo Sun
- Research Center, Eye & ENT Hospital, Fudan University, Shanghai 200031, China; Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University, Shanghai 200031, China; State Key Laboratory of Molecular Engineering of Polymers, Fudan University, Shanghai 200031, China.
| | - Xinghuai Sun
- Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China; Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University, Shanghai 200031, China.
| |
Collapse
|